Applying Genomic and Proteomic Microarray Technology in Drug Discovery

Microarrays play an increasingly significant role in drug discovery. Written by a leader in the field, Applying Genomic and Proteomic Microarray Technology in Drug Discovery highlights, describes, and evaluates current scientific research using microarray technology in genomic and proteomic applications. The author addresses the drawbacks, helping you avoid unnecessary pitfalls, and provides practical tips on how to employ the technology in drug discovery and development.

The book details the commercial landscape, covering the many issues surrounding the future adoption of gene expression and protein microarrays for pharmacogenomic and pharmacoproteomic applications. The author critically assesses those studies that have helped define applications in genomics and proteomics, explains gene expression microarray applications, and examines the utility of the protein microarray. He covers alternative substrates and the preparation of various surface chemistries together with their suitability for immobilization of nucleic acids and proteins. He delineates the mechanics of microarraying including environmental conditions, printer and pin performance, as well as discussion regarding setting up the print run. The book supplies protocols for printing nucleic acids and proteins and an in-depth discussion of other important parameters such as print buffers (inks) and factors influencing print quality.

An understanding of the making of a microarray is fundamentally important to those interested in producing "spotted" arrays and their proper use. As this technology expands in popularity and usefulness, industry experts must grasp the fundamental principles behind it, its strengths, and its limitations. A basic reference for users of microarray technology in drug discovery, this book offers a detailed perspective and insight into the present and future uses of this technology.

Robert S. Matson is president and co-founder of QuantiScientifics, LLC. The company is involved in the commercialization of multiplexed assays for life science, clinical research, and in vitro diagnostics. Previously, Matson was involved in the research and development of microarray technologies, detection chemistries, as well as point-of-care devices for more than 17 years while at Beckman Coulter, Inc. He participated in the National Institute of Standards and Technology’s (NIST) Advanced Technology Program sponsored Genosensor Consortium and collaborated with Sir Edwin Southern on the development of an in situ oligonucleotide array synthesis platform for the corporation. Other work included development of the A2 MicroArray System, a microplate-based array platform for multiplexed micro-ELISA, which QuantiScientifics recently licensed for commercialization.